Trial Profile
A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Mar 2023
Price :
$35
*
At a glance
- Drugs Inbakicept (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2023 Status changed from active, no longer recruiting to completed.
- 05 Dec 2022 Planned End Date changed from 31 Mar 2023 to 30 Jun 2023.
- 05 Dec 2022 Planned primary completion date changed from 31 Oct 2022 to 31 Mar 2023.